Overview

Dr. Dale Bredesen and Dr. Kaj Blennow explore one of 2024's most talked-about biomarkers for Alzheimer's disease - plasma p-Tau217. Recognized globally as a potential game-changer, p-Tau217 has been featured in thousands of news outlets and is emerging as a leading tool for early detection and diagnosis.

This session offers valuable insights into the biomarker's significance, its role in advancing Alzheimer's screening, and concludes with an in-depth overview of the Alzheimer's Assessment (p-Tau217), now available from Genova Diagnostics.